Rebecca (Becky) Noel is currently the Global Leader for Benefit-Risk Assessment at Eli Lilly. Since joining Lilly, Becky has been extensively involved in leading the development of systematic approaches to benefit-risk assessment, both internally at Lilly and externally via the PhRMA Benefit-Risk Action Team (BRAT), the Innovative Medicines Initiative PROTECT project, the International Conference on Harmonization, and via multiple other forums.

Emeritus Professor of Decision Sciences at the London School of Economics. Awarded the Frank P. Ramsey medal in 2005 for "distinguished contributions to decision analysis" by the Decision Analysis Society of INFORMS. From 2009-11 led a research project on benefit-risk modeling for the EMA.

Diana has a medical degree from the UK, is Board certified in Psychiatry in the US, has an MSc in Pharmaceutical medicine: 11 years of Safety and risk management experience at Pfizer, and has been involved in several B/R initiatives including those within PhRMA, CIRS, NSWG and IMI PROTECT.